Social Media-based Active Self-report on Incidence and Outcomes of Adverse Events in NK/TCL Patients
Social Media-based Patient Education and Active Self-report on Incidence and Outcomes of Adverse Events in Natural Killer/T-cell Lymphoma (NK/TCL) Patients
1 other identifier
observational
665
1 country
2
Brief Summary
The purpose of this study is to collect data from patients by social media and self-report on the adverse events and outcomes happened with patients with extranodal natural killer/T-cell lymphoma, nasal type, who are treated outside of clinical trials in China.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2017
Longer than P75 for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 8, 2017
CompletedFirst Submitted
Initial submission to the registry
March 9, 2017
CompletedFirst Posted
Study publicly available on registry
March 14, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 30, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
August 30, 2021
CompletedSeptember 14, 2021
September 1, 2021
4.5 years
March 9, 2017
September 13, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
overall survival
The overall survial time of patients will be measured since the initiation of treatment to death of any reason.
2-year
Secondary Outcomes (2)
Treatment-Related Adverse Events as Assessed by CTCAE v4.0
Day 1 of each course of chemotherapy and radiotherapy then every 3 months for 2 years
Progression free survival
2-year
Interventions
Patients receive at least one cycle of combinational chemotherapy containing L-asparaginas or Pegaspargase.
Eligibility Criteria
All patients with the diagnosis of NK/TCL treated out of clinical trials are candidators for this study.
You may qualify if:
- Pathological diagnosis of extranodal natural killer/T-cell lymphoma, nasal type based on WHO 2008 classification of tumors of haematopoietic and lymphoid tissue.
- Treated with at least one cycle of L-asparaginas or Pegaspargase based chemotherapy.
- Signed Informed consent.
You may not qualify if:
- patients who are enrolled in any other clinical trials.
- Relapsed patients who were initially treated with non-L-asparaginas or non-pegaspargase based regimens.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Rong Taolead
Study Sites (2)
Lymphoma House086
Beijing, Beijing Municipality, 100010, China
Xinhua Hospital
Shanghai, Shanghai Municipality, 200092, China
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Rong Tao, MD
Xinhua hospital, Shanghai Jiao Tong University of Medicine
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Clinical Professor
Study Record Dates
First Submitted
March 9, 2017
First Posted
March 14, 2017
Study Start
March 8, 2017
Primary Completion
August 30, 2021
Study Completion
August 30, 2021
Last Updated
September 14, 2021
Record last verified: 2021-09
Data Sharing
- IPD Sharing
- Will not share